China Next-Generation Sequencing Market

The China next-generation sequencing market is projected to grow from USD 1.35 billion in 2026 to USD 2.84 billion by 2031, at a CAGR of 16.0% during the forecast period. The market is expanding rapidly due to advancements in sequencing platforms, declining costs of sequencing technologies, increasing demand for precision medicine, and rising clinical applications across the healthcare and pharmaceutical research sectors.

The China next-generation sequencing market is dominated by major players, including Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), MGI Tech (China), BGI Group (China), Berry Genomics (China), and Novogene Co., Ltd. (China). Leading players stay competitive by launching advanced sequencing platforms, expanding bioinformatics capabilities, integrating artificial intelligence and machine learning for data analytics, forming strategic partnerships with research institutions and healthcare providers, and delivering cost-effective, high-throughput sequencing solutions across clinical diagnostics, oncology, and genomic research applications.

To know about the assumptions considered for the study download the pdf brochure

Illumina, Inc. (US) is a leading provider of next-generation sequencing platforms and comprehensive genomic solutions serving research, clinical, and applied markets worldwide. The company's sequencing technology enables high-throughput, accurate, and cost-effective analysis of genetic variation and biological function. Illumina delivers a full suite of products and services, including sequencing instruments, consumables, bioinformatics tools, and data analysis software for applications spanning oncology, reproductive health, genetic disease research, and population genomics. With decades of innovation and a dominant market position, Illumina has established itself as a trusted partner for academic institutions, pharmaceutical companies, and clinical laboratories seeking reliable sequencing solutions.

Thermo Fisher Scientific Inc. (US) is a technology-driven life sciences company specializing in comprehensive next-generation sequencing solutions for clinical diagnostics, pharmaceutical development, and academic research across global markets. Integrating sequencing platforms, reagents, and bioinformatics software into a single workflow, Thermo Fisher significantly reduces complexity, cost, and turnaround time compared to traditional sequencing methods. Its proprietary Ion Torrent sequencing technology and automated laboratory systems enable scalable genomic analysis for applications such as cancer profiling, infectious disease detection, and hereditary disorder screening. Thermo Fisher's complete sample-to-insight solutions, including library preparation, sequencing instruments, data analysis tools, and technical support, offer researchers and clinicians a turnkey platform that accelerates discovery and diagnostic accuracy without compromising data quality.

Market Ranking

Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), MGI Tech (China), BGI Group (China), Berry Genomics (China), and Novogene Co., Ltd. (China) are the leading companies in the China next-generation sequencing market. Illumina, Inc. is recognized for its high-throughput sequencing platforms and comprehensive genomic analysis solutions for clinical diagnostics and research applications, supported by extensive global infrastructure and continuous innovation in sequencing chemistry. Thermo Fisher Scientific Inc. specializes in Ion Torrent semiconductor sequencing technology, integrating automated workflows, targeted sequencing panels, and bioinformatics software for oncology, genetic disease, and infectious disease applications. MGI Tech is a major player in China’s NGS market, supported by its DNBSEQ sequencing platform portfolio for high-throughput and clinical research applications. BGI Group leverages its strong genomics ecosystem in China through broad sequencing and bioinformatics service capabilities for research, clinical molecular diagnostics, and precision medicine.

Related Reports:

China Next-Generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Platforms, Bioinformatics), Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com